Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:07:12.445Z.
Calculation as of: 2026-10-06T14:07:12.445Z.
Quote observation: 2026-10-06T14:05:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 44fde230bfdd574c3cd4cd53b0628620ec84ec898484da9a9f15813d4ff0e801
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$573.32M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$570.28M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$602.48M
EV/EBITDA Ratio
3.87x
TTM Avg
7.68x
3Y Avg
8.80x
5Y Avg
8.39x
Market Cap
$566.48M
EV/EBITDA Ratio
N/A
TTM Avg
42.12x
3Y Avg
42.12x
5Y Avg
42.12x
Market Cap
$557.41M
EV/EBITDA Ratio
N/A
TTM Avg
13.55x
3Y Avg
10.69x
5Y Avg
10.69x
Market Cap
$625.77M
EV/EBITDA Ratio
N/A
TTM Avg
8.45x
3Y Avg
304.75x
5Y Avg
435.98x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $583.05M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $573.32M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $570.28M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $602.48M | 3.87x | 7.68x | 8.80x | 8.39x |
| Aquestive Therapeutics, Inc. (AQST)vs › | $566.48M | N/A | 42.12x | 42.12x | 42.12x |
| CorMedix Inc. (CRMD)vs › | $564.07M | 1.79x | 5.90x | 15.41x | 15.41x |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.41M | N/A | 13.55x | 10.69x | 10.69x |
| AngioDynamics, Inc. (ANGO)vs › | $625.77M | N/A | 8.45x | 304.75x | 435.98x |
| Climb Bio, Inc. (CLYM)vs › | $628.75M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
